London, June 18, 2014: MRC Technology, a technology transfer organisation, announced today that it has sold to Pfizer Inc. its melanocortin receptors (MCRs) programme, which includes a set of small molecules. Targets for these small molecules came to the attention of MRC Technology from Mauro Perretti, Professor of Immunopharmacology at Queen Mary University of London …
Continue reading “MRC Technology Sells Its Melanocortin Receptors Programme To Pfizer Inc. (PFE)”